Investment in pharma manufacturing likely to get boost says Mr. Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA). Launch of the National digital health Eco System and National Tele Mental Health Programme will go a long way to serve health care needs of society.
New Delhi, February I : The Indian Pharmaceutical Alliance (IPA) has welcomed the union budget. Mr. Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA) said, ” This is India’s first post vaccination budget and the policy consistency is maintained. The planned increase in capital expenditure is likely to boost economic growth and employment. There is a thrust on macro areas like digital, VC-ecosystem, ease of doing business and supportive measures for R&D and industry-academia collaboration with Pharma included in the Sunrise sectors.
The extension time limit for the commencement of business to claim benefits of concessional tax regime for manufacturing companies has been extended by a year to 31 March 2024. This will support the investment in pharma manufacturing. Details are being examined and the implementation will be key going forward., he added.
According to Vinod Jain , CFO of Cadila Pharmaceuticals ltd the budget is a growth and development-oriented budget with focus on infrastructure, transport & logistic, manufacturing, education, health, and digital economy. He further added ” The budget emphasizes supportive policies, regulations, and ease of doing business to build domestic capacities, promote R&D and generate employment opportunities which will ensure sustainable growth for the country in years to come. Launch of the National digital health Eco System and National Tele Mental Health Programme will go a long way to serve health care needs of society. “
